Dynavax Technologies | DVAX - Loan Capital

Stock Price
15.50
Daily Change
0.01 0.03%
Monthly
0.55%
Yearly
17.83%
Q1 Forecast
15.01

Dynavax Technologies reported $220.97M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Adma Biologics USD 70.08M 3.32M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
AstraZeneca USD 6.55B 19.43B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Dynavax Technologies USD 220.97M 214K Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Glaxosmithkline GBP 20.02B 4.72B Sep/2025
Merck USD 39.97B 6B Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 24.24B 174M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
TG Therapeutics USD 245.34M 303K Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025